| Hotline III - Acute coronary syndromes | |
 | PRODIGY Randomized comparison of six versus twenty-four months of clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention Marco Valgimigli, Azienda Ospedaliero-Universitaria Sant’Anna, Ferrara, Italy Presentation slides | Summary slide |
 | The RUBY-1 trial Safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischemic vascular events in patients following an acute coronary syndrome Philipe Gabriel Steg, Hôpital Bichat-Claude Bernard, Service de Cardiologie, Paris, France Presentation slides | Summary slide |
 | Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early-generation sirolimus-eluting and paclitaxel-eluting stents Lorenz Räber, Berne University Hospital, Switzerland Presentation slides | Summary slide |
 | CRISP AMI |
 | EXAMINATION trial A randomized comparison between everolimus-eluting stent and bare-metal stent in patients with ST-segment-elevation myocardial infarction Manuel Sabaté, Hospital de Sant Pau, Barcelona, Spain Summary slide |
